18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer

The aim of this prospective study was to assess the ability of 18F-fluorodeoxyglucose ((18)FDG) positron emission tomography/computed tomography (PET/CT) scanning to predict pathological complete response (pCR) in breast cancer, and to investigate whether timing of the scan and trastuzumab treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jingyi, Wang, Yujie, Mo, Miao, Bao, Xiao, Zhang, Yingjian, Liu, Guangyu, Zhang, Jun, Geng, Daoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745734/
https://www.ncbi.nlm.nih.gov/pubmed/26336821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745734/
https://www.ncbi.nlm.nih.gov/pubmed/26336821

Ejemplares similares